Estados Unidos - inglês - NLM (National Library of Medicine)

carilion materials management - rifaximin (unii: l36o5t016n) (rifaximin - unii:l36o5t016n) - rifaximin 200 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of xifaxan and other antibacterial drugs, xifaxan when used to treat infection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. xifaxan is indicated for the treatment of travelers’ diarrhea (td) caused by noninvasive strains of escherichia coli in adults and pediatric patients 12 years of age and older. limitations of use xifaxan should not be used in patients with diarrhea complicated by fever or blood in the stool or diarrhea due to pathogens other than escherichia coli [see warnings and precautions (5.1), clinical pharmacology (12.4), clinical studies (14.1)]. xifaxan is indicated for re

Estados Unidos - inglês - NLM (National Library of Medicine)

dispensing solutions, inc. - rifaximin (unii: l36o5t016n) (rifaximin - unii:l36o5t016n) - rifaximin 200 mg -         to reduce the development of drug-resistant bacteria and maintain the effectiveness of xifaxan and other antibacterial drugs, xifaxan when used to treat infection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.  when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.  in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.         xifaxan 200 mg is indicated for the treatment of patients (≥ 12 years of age) with travelers’ diarrhea caused by

Estados Unidos - inglês - NLM (National Library of Medicine)

physicians total care, inc. - rifaximin (unii: l36o5t016n) (rifaximin - unii:l36o5t016n) - rifaximin 200 mg -         to reduce the development of drug-resistant bacteria and maintain the effectiveness of xifaxan and other antibacterial drugs, xifaxan when used to treat infection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.  when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.  in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.         xifaxan 200 mg is indicated for the treatment of patients (≥ 12 years of age) with travelers’ diarrhea caused by

Panamá - inglês - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

laboratorios stein, s.a - rifaximina - rifaximina....550,0000 mg

Reino Unido - inglês - MHRA (Medicines & Healthcare Products Regulatory Agency)

norgine pharmaceuticals ltd - rifaximin - oral tablet - 550mg

Irlanda - inglês - HPRA (Health Products Regulatory Authority)

norgine b.v. - rifaximin - film-coated tablet - 550 milligram(s) - antibiotics; rifaximin

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

carsl consulting - rifaximin 550mg;  ;  ;   - film coated tablet - 550 mg - active: rifaximin 550mg       excipient: colloidal silicon dioxide disodium edetate glyceryl diisostearate hypromellose iron oxide red microcrystalline cellulose propylene glycol purified talc purified water sodium starch glycolate titanium dioxide - prevention of the recurrence of hepatic encephalopathy where other treatments have failed or are contraindicated.

Estados Unidos - inglês - NLM (National Library of Medicine)

a-s medication solutions - rifaximin (unii: l36o5t016n) (rifaximin - unii:l36o5t016n) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of xifaxan and other antibacterial drugs, xifaxan when used to treat infection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. xifaxan is indicated for the treatment of travelers’ diarrhea (td) caused by noninvasive strains of escherichia coli in adults and pediatric patients 12 years of age and older. limitations of use xifaxan should not be used in patients with diarrhea complicated by fever or blood in the stool or diarrhea due to pathogens other than escherichia coli [see warnings and precautions (5.1), clinical pharmacology (12.4), clinical studies (14.1)]. xifaxan is indicated for re

Reino Unido - inglês - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - rifaximin - oral tablet - 200mg

Reino Unido - inglês - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - rifaximin - oral suspension - 20mg/1ml